Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2005-07-19
2005-07-19
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S468000, C514S534000, C514S579000, C514S646000, C514S663000, C514S727000, C514S729000, C514S730000
Reexamination Certificate
active
06919092
ABSTRACT:
A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.
REFERENCES:
patent: 2799241 (1957-07-01), Wurster
patent: 2996431 (1961-08-01), Barry
patent: 3139383 (1964-06-01), Neville
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4111202 (1978-09-01), Theeuwes et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4434153 (1984-02-01), Urquhart
patent: 4612008 (1986-09-01), Wong et al.
patent: 4721613 (1988-01-01), Urquhart
patent: 4752470 (1988-06-01), Mehta
patent: 4783337 (1988-11-01), Wong et al.
patent: 4800098 (1989-01-01), Galland
patent: 4816263 (1989-03-01), Ayer et al.
patent: 4824675 (1989-04-01), Wong et al.
patent: 4853229 (1989-08-01), Theeuwes
patent: 4863456 (1989-09-01), Stephens et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 5399359 (1995-03-01), Baichwal
patent: 5674895 (1997-10-01), Guittard et al.
patent: 5811126 (1998-09-01), Krishnamurthy
patent: 5840754 (1998-11-01), Guittard et al.
patent: 5912268 (1999-06-01), Guittard et al.
patent: 6124355 (2000-09-01), Guittard et al.
patent: 6262115 (2001-07-01), Guittard et al.
patent: WO 96/12477 (1996-05-01), None
patent: WO 96/37202 (1996-11-01), None
Abdou, H.M., “Dissolution,” Remington's Pharmaceutical Sciences, 17thEd., 1985,Chapter 35, 653-666.
Anderberg, E.K., et al., “Physicochemical aspects of drug release—X. Investigation of the applicability of the cube root law for characterization of the dissolution rate of fine particulate materials,”International Journal of Pharmaceutics, 1990, 62, 143-151.
Enomoto, et al., “Sustained release formulations containing oxybutynin chloride,”Chemical Abstracts, Apr. 4, 1994, 120(14), 173491.
Enomoto, et al., “Sustained release preparation of oxybutynin chloride,”Chemical Abstracts, May 2, 1994, 120(18), 227011.
Grafton, P., “General principles for designing with plastics,” Modern Plastics Encyclopedia, Oct. 1969, 46(10A), 62-70.
Nisson, C.G., et al., “Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in incontinent patients,”Neurology&Urodynamics, 1997, XP002099745, 16, 533-542.
The United States Pharmacopeia/The National Formulary, “Dissolution,”USP XXII, NF XVII, Jan. 1, 1990, 711, 1578-1579.
The United States Pharmacopeia/The National Formulary, “Dissolution,”USP 23/NF18, Jan. 1, 1995, 711, 1791-1796.
The United States Pharmacopeia/The National Formulary, “Test solutions,”UPS 23/NF 180, Jan. 1, 1995, 2052-2053.
Kodama, K.K., “Sustained release preparation of oxybutynin chloride—comprises oxybutynin chloride, acidic substance, gelling agent and higher alcohol,”Database WPI, Derwent Publication Ltd., London, GB, AN 94-068306, XP002096606, Jan. 18, 1994, 1 page.
Kodama, K.K., “Pharmaceutical preparations for prolonged action against urinary incontinence—comprise sustained release oxybutynin chloride for pharmaceutical compsn. sustained release coating film on non water soluble polymers and/or ethylcellulose,”Database WPI, Derwent Publication Ltd, London, GB, AN 94-031722, XP002096607, Dec. 21, 1993, 1 page.
Gupta, S. K. et al. “Evidence of Site-Specific Presystemic Methabolism of Oxybutynin Following Oral Administration,”Clinical Pharmacology&Therapeutics, vol. 61, No. 2, 1997, P. 227 XP002096606.
Lu, S. M., Yu, Y. J. “Dimensionless Presentation for Drug Release from a Coated Pure Drug Bead: 2 Experiment,” Inter. J. Of Pharm., vol. 112, pp. 117-124 (1994).
Remington's Pharmaceutical Sciences, 14thEd., pp. 1626-1628 (1970).
Fincher, J. “Particle Size of Drug and Its Relationship to Absorption and Activity,” Journal of Pharmaceutical Sciences, vol. 57, No. 11, pp. 1825-1835 (1986).
Remington's Pharmaceutical Sciences, 17thEd., pp. 1603-1625 (1985).
Rosoff, M. “Polymers and Aggregate Systems,”Controlled Release of Drugs, Chapter 2, pp. 53-95 (1989).
Coleman, M. et al., “A practical Guide to Polymer Miscibility,”Polymer Reviews, vol. 31, pp1187-1231 (1990).
Roerdink et al., “Drug Carrier Systems,” vol. 9, pp. 57-109 (1989).
Leong et al., “Polymeric Controlled Drug Delivery,” vol. 1, pp. 199-233 (1987).
Roff et al., “Handbook of Common Polymers,” published by CRC Press (1971).
Chemical Abstracts, vol. 120, No. 18, May 2, 1994, Abstract No. 227011.
Chemical Abstracts, vol. 120, No. 14, Apr. 4, 1994, Abstract No. 173499.
“General principles for designing with plastics” by P. Grafton, 1969-1970 Modern Plastics Encyclopedia, vol. 46, pp 62-70.
“Preparation of Compressed Tablet Granulations by the Air-Suspension Technique II” by Dale E. Wurster, J. of Amerc. Phar. Association Vol. 49 No. 2, pp 82-84.
“Air-Suspension Technique of Coating Drug Particles” by Dale E. Wurster, J. Am Phar. Assoc. Sci. Ed., vol. 48, pp. 451454, Aug. 1959.
Pharmaceutical Science, by Remington, 14th Ed., pp 1626-1979, (1970).
Guittard George V.
Gumucio Fernando E.
Jao Francisco
Kidney David J.
Marks Susan M.
ALZA Corporation
Dodson Shelley A.
George Konata M
Woodcock & Washburn LLP
LandOfFree
Method for the management of incontinence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the management of incontinence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the management of incontinence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3418600